Ventures

Audaxis Medical revolutionizes the treatment of stress urinary incontinence with Plielle™, a next-generation polyurethane support system. While traditional polypropylene slings often lead to chronic inflammation and tissue complications, Plielle™ offers a safer alternative by replicating the native structure and viscoelastic properties of the pelvic floor. By providing a high-performance, biocompatible solution that integrates seamlessly with human tissue, Audaxis aims to improve clinical outcomes and restore patient confidence, filling a critical gap in women’s healthcare.

Spinal cord Injury represents a large unmet medical need with approximately 1.2M new cases per year resulting mainly from motor vehicle accidents, falls and water related accidents. Currently available treatments only offer symptomatic relief but do not target the underlying pathophysiologic changes. The spinal cord injury market is predicted to reach US$3B by 2025. MLP-1236 is a First in class dual inhibitor of matrix metalloproteinases (MMP) 9 and MMP 12 and has already completed Phase 1 and Phase 2a clinical studies. In preclinical models, MLP-1236 was effective in preventing/reversing the neurodegeneration associated with spinal cord injury and ischemic stroke.

Amotio addresses the challenge of revision surgeries for hip, knee, and shoulder implants with their innovative approach. Collaborating with expert revision surgeons and guided by NLC, they offer a patented solution for improved implant revision surgery. By developing unique bone cement removal devices and integrating advanced patient-specific 3D surgical planning and printing technology, Amotio aims to set a new standard for excellence in these surgeries. Their goal is to reduce complexity, trauma, and recovery time while cutting costs for healthcare providers.

Implant Preservation Devices has developed a handheld device to tackle a common problem after joint replacement surgeries prosthetic joint infections (PJI). This device applies heat to implants using induction, effectively targeting and eliminating bacteria that cause these infections. By reducing the risk of recurrent infections, it offers a quick, sterile, and convenient treatment option during surgery, potentially benefiting patients beyond just those undergoing joint replacements.

Nicolab tackles the challenge of stroke diagnosis and treatment by offering computational support through their portfolio of six algorithms. These algorithms analyze radiological images of acute stroke patients, providing fast and objective interpretation for physicians. With stroke affecting millions annually and significant economic burdens, Nicolab's solution improves decision-making speed and accuracy, allowing clinicians to assess stroke severity objectively and make timely treatment decisions.

Rheumasense combines LC-MS biomarker testing with advanced machine learning to provide real-time, objective insights into rheumatoid arthritis (RA) disease activity. Our technology measures specific metabolites linked to RA progression, offering accurate, quantitative data for timely, personalized treatment adjustments. With a simple at-home blood collection kit and clinically validated testing at Mayo Clinic Laboratories, we deliver actionable results quickly and cost-effectively, improving patient outcomes and supporting proactive care.

Intercept TX is developing a first-in-class, orally available small-molecule therapy targeting the RAGE/DIAPH1 pathway, a central but underexploited disease axis in chronic metabolic and inflammatory conditions including type 2 diabetes, obesity and MASH. While existing treatments manage symptoms, they fail to address underlying disease progression. Intercept TX's approach targets the root of metabolic stress, inflammation and fibrosis, in a single platform with applicability across multiple high-value, multi-billion-euro markets.

Revadix is a pioneering biotech venture focused on transforming the treatment of atrial fibrillation (AF), a common heart rhythm disorder. The company is developing AM-001, a novel therapy that targets the EPAC-1 protein, aiming to restore normal heart rhythm and offer a curative solution rather than just symptom management. Revadix’s approach promises to improve patient outcomes with fewer side effects and better long-term health results. Supported by NLC Health Ventures, the company is advancing AM-001 towards clinical trials, with the potential to revolutionize cardiovascular care.